Περίληψη:
Recent advances in the treatment of multiple myeloma have increased the
need for accurate diagnosis of the disease. The detection of bone and
bone marrow lesions is crucial in the investigation of multiple myeloma
and often dictates the decision to start treatment. Furthermore,
detection of minimal residual disease is important for prognosis
determination and treatment planning, and it has underscored an unmet
need for sensitive imaging methods that accurately assess patient
response to multiple myeloma treatment. Low-dose whole-body CT has
increased sensitivity compared with conventional skeletal survey in the
detection of bone disease, which can reveal information leading to
changes in therapy and disease management that could prevent or delay
the onset of clinically significant morbidity and mortality as a result
of skeletal-related events. Given the multiple options available for the
detection of bone and bone marrow lesions, ranging from conventional
skeletal survey to whole-body CT, PET/CT, and MRI, the International
Myeloma Working Group decided to establish guidelines on optimal use of
imaging methods at different disease stages. These recommendations on
imaging within and outside of clinical trials will help standardise
imaging for monoclonal plasma cell disorders worldwide to allow the
comparison of results and the unification of treatment approaches for
multiple myeloma.
Συγγραφείς:
Hillengass, Jens
Usmani, Saad
Rajkumar, S. Vincent
Durie,
Brian G. M.
Mateos, Maria-Victoria
Lonial, Sagar
Joao,
Cristina
Anderson, Kenneth C.
Garcia-Sanz, Ramon
Riva Serra,
Eloisa
Du, Juan
van de Donk, Niels
Berdeja, Jesus G. and
Terpos, Evangelos
Zamagni, Elena
Kyle, Robert A.
San Miguel,
Jesus
Goldschmidt, Hartmut
Giralt, Sergio
Kumar, Shaji and
Raje, Noopur
Ludwig, Heinz
Ocio, Enrique
Schots, Rik and
Einsele, Hermann
Schjesvold, Fredrik
Chen, Wen-Ming and
Abildgaard, Niels
Lipe, Brea C.
Dytfeld, Dominik
Wirk,
Baldeep Mona
Drake, Matthew
Cavo, Michele
Jose Lahuerta,
Juan
Lentzsch, Suzanne
